Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Why Aligos Therapeutics Stock Crumbled Today

TheMotleyFool

0 0

Why Aligos Therapeutics Stock Crumbled TodayPhoto, wide shot, wide-angle lens, Mental health care service, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ce3b930-5e2a-4215-b686-0ad0eb0b922a.png

Clinical-stage biotech Aligos Therapeutics (NASDAQ: ALGS) had some bad news to report on Thursday. As a result, unforgiving investors sent the company's stock down by almost 57%, making it one of the sector's steepest decliners today.

Biotechs without any commercialized products are heavily dependent on the results of the clinical trials for their pipeline programs. This was the issue with Aligos on Thursday; in the morning the company divulged that it is halting the further development of its experimental drug ALG-010133, which targets chronic hepatitis B (CHB).

Image source: Getty Images.

Source Fool.com

Like: 0

ALGS

Teilen